Research Analysts Issue Forecasts for Sarepta Therapeutics Inc.’s FY2020 Earnings (SRPT)
Sarepta Therapeutics Inc. (NASDAQ:SRPT) – Equities research analysts at Wedbush raised their FY2020 earnings per share (EPS) estimates for Sarepta Therapeutics in a research report issued to clients and investors on Tuesday. Wedbush analyst H. Behanna now forecasts that the firm will earn $2.33 per share for the year, up from their prior estimate of $2.18. Wedbush currently has a “Outperform” rating and a $66.00 target price on the stock.
Other analysts also recently issued reports about the company. Oppenheimer Holdings Inc. upped their price objective on Sarepta Therapeutics from $60.00 to $76.00 in a report on Monday, September 19th. Needham & Company LLC upped their price objective on Sarepta Therapeutics from $20.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, July 22nd. Robert W. Baird restated a “buy” rating on shares of Sarepta Therapeutics in a report on Friday, June 10th. Janney Montgomery Scott upgraded Sarepta Therapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $30.00 to $65.00 in a report on Monday, September 19th. Finally, Piper Jaffray Cos. set a $68.00 price objective on Sarepta Therapeutics and gave the stock a “buy” rating in a report on Tuesday. One analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $58.12.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded down 5.78% during mid-day trading on Wednesday, reaching $58.17. The company’s stock had a trading volume of 8,153,244 shares. The firm has a 50-day moving average of $40.06 and a 200-day moving average of $25.13. The firm’s market capitalization is $2.79 billion. Sarepta Therapeutics has a 52 week low of $8.00 and a 52 week high of $63.73.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same period in the prior year, the firm earned ($0.87) earnings per share.
In other Sarepta Therapeutics news, SVP David T. Howton sold 7,000 shares of the firm’s stock in a transaction dated Thursday, September 22nd. The shares were sold at an average price of $60.00, for a total value of $420,000.00. Following the transaction, the senior vice president now owns 28,453 shares of the company’s stock, valued at $1,707,180. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Edward M. Md Kaye sold 24,557 shares of the firm’s stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of $30.00, for a total transaction of $736,710.00. Following the completion of the transaction, the chief executive officer now directly owns 76,983 shares in the company, valued at approximately $2,309,490. The disclosure for this sale can be found here. 10.90% of the stock is currently owned by company insiders.
Institutional investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA boosted its position in shares of Sarepta Therapeutics by 114.0% in the third quarter. BNP Paribas Arbitrage SA now owns 3,541 shares of the company’s stock worth $217,000 after buying an additional 1,886 shares in the last quarter. Teacher Retirement System of Texas raised its stake in shares of Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock valued at $115,000 after buying an additional 724 shares during the last quarter. Advisor Group Inc. purchased a new stake in shares of Sarepta Therapeutics during the second quarter valued at approximately $154,000. Quantitative Systematic Strategies LLC purchased a new stake in shares of Sarepta Therapeutics during the second quarter valued at approximately $211,000. Finally, First Allied Advisory Services Inc. raised its stake in shares of Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock valued at $245,000 after buying an additional 800 shares during the last quarter. 65.29% of the stock is currently owned by hedge funds and other institutional investors.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.